NASDAQ · CLPT
ClearPoint Neuro, Inc.
Healthcare · Medical - Devices
$9.81▼ 3.82% ($0.39)at close
As of 4:00 PM ET
Market cap
$294.20M
P/E
N/M
EPS (TTM)
-$1.16
Next earnings
Nov 5, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Enterprise value of $19.07M does not cover net debt of $21.06M, so equity value is negative and no fair value per share can be shown. 7 of 10 projected years carry negative free cash flow. This engine cannot separate captive-finance or other non-operating borrowings from operating debt.
- 10-yr revenue CAGR
- 12.4%
- Ending operating margin
- 0.0%
- Discount rate
- 10.1%
USD · TTM ending Jun 30, 2026 · Price used $9.81 · Price Oct 13, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 62.66% over the last year. Revenue grew 25.86% over the trailing twelve months. Operating margin moved from -67.33% to -73.42%. Free cash flow declined 167.09% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -73.42%. A decisive move in revenue — currently up 25.86% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States.
Market multiples
Stock splits
Every 40 shares became 1
Profitability & growth
Analyst consensus
3
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 5, 2026
Q3 FY26 · EPS est -$0.27 · Revenue est $12.3M
Q2 FY26
Reported Aug 3, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.38
Estimate
-$0.29
Year over year
n/m
Vs prior quarter
n/m
4 misses in the last 4 quarters
Institutional Sentiment
ClearPoint Neuro, Inc. · CLPT
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.